Render Target: SSR
Render Timestamp: 2024-10-24T19:25:43.173Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-09-20 06:23:10.742
Product last modified at: 2024-10-16T00:00:08.871Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human IL-6 Recombinant Protein #48333

    Product Information

    Storage

    Human IL-6 Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/ml which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage.

    Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.

    Product Description

    MW (kDa) 21
    Purity A greater than or equal to 95% purity was determined by SDS-PAGE.
    Endotoxin Endotoxin levels are less than or equal to 1 EU / 1 μg hIL-6.
    Activity The bioactivity of recombinant hIL-6 was determined in a B9 cell proliferation assay. The ED50 of each lot is less than or equal to 25 pg/ml.

    Source / Purification

    Recombinant human IL-6 was expressed in E. coli and is supplied in a lyophilized form.

    Background

    Acute phase response is induced by interleukin-6 (IL-6) produced by T cells, macrophages, fibroblasts, endothelial and other cells (1,2). IL-6 induces proliferation or differentiation in many cell types including B cells, thymocytes and T cells. IL-6, in concert with TGF-β, is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP-2/Erk MAP kinase cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane-associated (3). The IL-6/soluble IL-6Rα complex can then activate the gp130 signaling pathway in cells that express gp130 but not IL-6Rα (3). Research studies have shown that IL-6, through increasing expression of proangiogenic VEGF, may also contribute to metastatic breast cancer (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.